Overview

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

AIO-KHT-0117 (OPTIM) is a phase II, open-label randomized, multicenter study of nivolumab and ipilimumab on the optimization of immunotherapy in squamous carcinoma of the head and neck after prior platinum-based therapy.

Phase:

Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Docetaxel
Ipilimumab
Nivolumab